托特罗定联合坦索罗辛治疗前列腺增生合并膀胱过度活动症临床研究

Clinical Study on Tolterodine Combined with Tamsulosin in the Treatment of Prostatic Hyperplasia Complicated with Overactive Bladder

目的探讨托特罗定联合坦索罗辛治疗前列腺增生合并膀胱过度活动症的临床疗效。方法选取医院2015年2月至2016年2月收治的前列腺增生合并膀胱过度活动症患者87例,按随机数字表法分为对照组(41例)和研究组(46例)。对照组患者给予盐酸坦索罗辛缓释胶囊口服,研究组患者在此基础上加服酒石酸托特罗定片。结果与治疗前比较,两组患者治疗后的前列腺症状评分(IPSS)、膀胱过度活动症评分(OABSS)均明显降低(P <0. 05),残余尿量、尿急次数明显减少,最大尿流率明显升高(P <0. 05),且研究组上述指标改善水平明显优于对照组(P <0. 01);研究组不良反应发生率为2. 17%,明显低于对照组的14. 63%(P <0. 05)。结论托特罗定联合坦索罗辛治疗前列腺增生合并膀胱过度活动症,可降低IPSS和OABSS评分,改善排尿状况,有效降低不良反应发生率。

Objective To investigate the clinical effect of tolterodine combined with tamsulosin in the treatment of prostatic hyperplasia complicated with overactive bladder.Methods Totally 87 patients with prostatic hyperplasia complicated with overactive bladder admitted to our hospital from February 2015 to February 2016 were selected and divided into the control group(41 cases)and the study group(46 cases)according to the random number table method.The patients in the control group were given Tamsulosin Hydrochloride Sustained-Release Capsules,on this basis,the patients in the study group were given Tolterodine Tartrate Tablets.Results Compared with before treatment,the International Prostate Symptom Score(IPSS)and Overactive Bladder Symptoms Score(0ABSS)were significantly decreased,the residual urine volume(RUV)and the urgent urination times were significantly reduced,the maximum urinary flow rate was significantly increased in the two groups after treatment(P<0.05),and the improvement of the study group was significantly better than that of the control group(P<0.05).The incidence rate of adverse reactions in the study group was 2.17%,which was significantly lower than 14.63%in the control group(P<0.05).Conclusion Tolterodine combined with tamsulosin in the treatment of prostatic hyperplasia complicated with overactive bladder can efectively reduce IPSS and OABSS,improve urination,and efectively reduce the incidence rate of adverse reactions.